In Y2014, several new agents targeted to castration resistant(recurrent)prostate cancer; CRPC, are approved in Japan.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Although such good news comes 2-3 years behind Western, it may improve the outcomes of the CRPC patients in Japan. In this issue, enzalutamide, abiraterone, and cabazitaxel are discussed by each experts from the productive industries. In addition, the experts from urological field and medical oncology field describe the role of each discipline.
Akaza H. Are you the author?
Research Center for Advanced Science and Technology (RCAST), the University of Tokyo.
Reference: Gan To Kagaku Ryoho. 2014 Jul;41(7):804.
Article in Japanese.